Michele Yang

OverviewAI-generated summary

Michele Yang's research focuses on the study of genetic and neuromuscular disorders, particularly Duchenne muscular dystrophy (DMD). Her work has investigated the efficacy and safety of therapeutic agents, such as vamorolone, over extended periods in pediatric populations with DMD. Yang has also explored the genetic underpinnings of neurodevelopmental disorders, including identifying loss-of-function mutations in the GEMIN5 gene. Her research extends to the development and validation of assessment tools, such as hyperphagia questionnaires for patients with Bardet-Biedl syndrome.

Her recent publications also address clinical considerations in managing rare genetic conditions, including gene therapy delivery for DMD and treatment outcomes for spinal muscular atrophy. Yang has contributed to understanding biomarker identification in DMD patient cohorts and has examined healthcare access during the COVID-19 pandemic, specifically the utilization of telemedicine in neurology.

Yang leads a research group and has a h-index of 26 with over 2,700 citations across 74 publications. She collaborates with other researchers at the University of Arkansas for Medical Sciences, including Aravindhan Veerapandiyan. Her recent activity indicates ongoing contributions to the field.

Metrics

• h-index: 26
• Publications: 74
• Citations: 2,732